Oncothyreon buys Alpine Biosciences for $26.2mm in stock
Cancer therapeutics developer Oncothyreon Inc. issued 9.3mm of its common shares (valued at $26.2mm based on the market average) to acquire Alpine Biosciences Inc., a privately held company utilizing a nanotechnology platform to develop targeted treatments for cancer and rare diseases.
- Large Molecule
- Nanotechnology, Chips, etc.
- Acquisition of Private Biotech
- Full Acquisition
- Includes Contract
- Intra-Biotech Deal
- Payment Includes Stock
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.